Lamotrigine and the treatment of mania in bipolar disorder

European Neuropsychopharmacology

Volumn 9, Issue SUPPL. 4, 1999, Pages

  Berk, M ^a  

^a UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

Author keywords

Bipolar disorder; Controlled trial; Lamotrigine; Mania; Mechanisms; Tolerability

Indexed keywords

LAMOTRIGINE;

CONFERENCE PAPER; DRUG TOLERANCE; HUMAN; MANIA; MANIC DEPRESSIVE PSYCHOSIS; PRIORITY JOURNAL;

ADULT; AFFECT; ANTIMANIC AGENTS; BIPOLAR DISORDER; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM; MALE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, GLUTAMATE; SODIUM CHANNELS; TRIAZINES;

EID: 0032764916     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(99)00025-5     Document Type: Conference Paper

References (31)

1. Bauer M.S. Bipolar disorder for the non-specialist: clinical features, morbidity, and management strategies. R.I. Med. 76:1993;399-404.
2. Berk M., Bodemer W., van Oudenhove T., Butkow N. The platelet intracellular calcium response to serotonin is augmented in bipolar manic and depressed patients. Human Psychopharmacol. 10:1995;189-193.
3. Berk M., Plein H., Csizmadia T. Supersensitive platelet glutamate receptors as a possible peripheral marker in schizophrenia. Int. Clin. Psychopharmacol. 14:1999;119-122.
4. Berk, M., Ichim, L., Brook, S., 1999. Olanzapine compared with lithium in mania: A double-blind randomised controlled trial. Int. Clin. Psychopharmacol., in press.
5. Bowden C.L. New concepts in mood stabilization: evidence for the effectiveness of valproate and lamotrigine. Neuropsychopharmacology. 19:1998;194-199.
6. Buller R. Variability of placebo response in anxiety disorders. Eur. Neuropsychopharmacol. 8:(suppl. 2):1998;S79-S80.
7. Buss T.J., Li R., Peiper S.C., El-Mallakh R.S. Lymphoblastoid transmembrane potential in bipolar patients, their siblings and unrelated healthy comparison subjects. Psychiatry Res. 59:1996;197-201.
8. Calabrese J., Bowden C., McElroy S., Cookson J., Andersen J. Lamictal monotherapy in the treatment of bipolar disorder. Eur. Neuropsychopharmacol. 7:1997;S177.
9. Calabrese, J., Bowden, C., McElroy, S., Cookson, J., Andersen, J., Keck, P., Rhodes, L., Bolden-Watson, C., Zhou, J., Ascher, J., 1999. Spectrum of activity of lamotrigine in treatment refractory bipolar disorder. Am. J. Psychiatry, in press.
10. Calabrese J.R., Bowden C.L., Sachs G.S., Ascher J.A., Monaghan E., Rudd G.D. for the Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Clin. Psychiatry. 60:1999;79-88.
11. Clark H.M., Berk M., Brook S. A randomised controlled single blind study of the efficacy of clonazepam and lithium in the treatment of acute mania. Human Psychopharmacol. 12:1997;325-328.
12. Cookson J. Lithium: balancing risks and benefits. Br. J. Psychiatry. 171:1997;120-124.
13. 1A receptor sensitivity in major depression: a neuroendocrine study with buspirone. Br. J. Psychiatry. 164:1994;372-379.
14. El-Mallakh R.S., Jaziri W.A. Calcium channel blockers in affective illness: role of sodium-calcium exchange. J. Clin. Psychopharmacol. 10:1990;203-206.
15. Fitton A., Goa K.L. Lamotrigine: An update of its pharmacology and therapeutic use in epilepsy. Drugs. 50:1995;691-713.
16. Fogelson D.L., Sternbach H. Lamotrigine treatment of refractory bipolar disorder. J. Clin. Psychiatry. 58:1997;271-273.
17. Gelenberg A.J., Kane J.M., Keller M.B., Lavori P., Rosenbaum J.F., Cole K., Lavelle J. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. New Engl. J. Med. 321:1989;1489-1493.
18. Hokin-Neaverson M., Jefferson J.W. Erythrocyte sodium pump activity in bipolar affective disorder and other psychiatric disorders. Neuropsychobiology. 22:1989;1-7.
19. Ichim, L., Berk, M., Brook, S., 1999. Lamotrigine compared with lithium in mania: A randomised controlled trial. Ann. Clin. Psychiatry, in press.
20. Isojärvi J., Laatikainen T., Pakarinen A., Juntunen K., Myllylä V. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. New Engl. J. Med. 329:1993;1383-1388.
21. Leach M.J., Marden C.M., Miller A.A. Pharmocological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia. 27:1986;490-497.
22. 1A) receptor-mediated hypothermic response to ipsapirone in unipolar depression. Life Sci. 46:1990;1271-1277.
23. Maj M., Pirozzi R., Magliano L., Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am. J. Psychiatry. 155:1998;30-35.
24. Mandoki M. Lamotrigine/valproate in treatment resistant bipolar disorder in children and adolescents. Annual Meeting of the Society for Biological Psychiatry, May 17, 1997, San Diego :1997.
25. Post R.M., Weiss S.R.B. A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures. Mol. Neurobiol. 13:1996;33-60.
26. 1A receptor function in healthy human males. J. Affect. Disord. 49:1998;157-162.
27. Sporn J., Sachs G. The anticonvulsant lamotrigine in treatment resistant manic-depressive illness. J. Clin. Psychopharmacol. 17:1997;185-189.
28. Walden J., Hesslinger B., van Calker D., Berger M. Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Pharmacopsychiatry. 29:1996;193-195.
29. Walden J. Is lamotrigine effective for treatment-refractory mania? Author's reply. Pharmacopsychiatry. 31:1998;35.
30. Walden J., Normann C., Langosch J., Berger M., Grunze H. Differential treatment of bipolar disorder with old and new antiepileptic drugs. Neuropsychobiology. 38:1998;181-184.
31. Xie X., Hagan R.M. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology. 38:1998;119-130.